Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CymaBay Therapeutics, Inc. (CBAY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.9000+0.1100 (+6.15%)
At close: 04:00PM EDT
1.9000 0.00 (0.00%)
After hours: 07:53PM EDT
Advertisement
Sign in to post a message.
  • B
    Bill
    Price will stay low until Seladepar is close to be approved. Then one of the big ones will buy the company or the patent and stock will jump to $12 or so. Then sell.
    Bullish
  • 💊C
    Would you look at that, a beautiful sale on the stock with one of the most guaranteed positive Phase 3 readouts in the coming year!
    Bullish
  • P
    Peter
    Anybody home at CBAY...talk about a slow burn to the bottom...No news is bad news for this house.
    Come on CBAY...let's have some press releases on progress toward end goals!!!
  • B
    Big Toe
    I really hope avro capital isn't selling this now
  • s
    sWINger
    $CORT conversation
    $SLS Phase 2 T Cell Gen Combination Data with $MRK Keytruda - Previous results had 100% patient survival at 9+ months in Platinum Refractory End stage Ovarian cancer. Enrollment was completed and data locked for Joint analysis in May/June Timeframe. Anyone (serious question) have an opinion on this. Would appreciate it.

    https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html
    $SWTX Ph 3
    $ADAG Ph 2
    $CCCC
    $PRLD
    $KPTI
    $ICPT Ph 3
    $IMMP Ph 2
    $VERU Ph 2
    $DMAC Ph 2
    $KLDO Ph 2
    $MREO Ph 2
    $SLS Ph 2
    $CORT Ph 2
    $CRBP Ph 2
    $PRAX Ph 2
    $AMRN Ph 2
    $ZEAL Ph 3
    $CBAY Ph 2
    $ARVN Ph 2
    $TNXP Ph 3
    $FGEN Ph 2

    $SWTX Ph 3
    $ADAG Ph 2
    $CCCC
    $PRLD
    $KPTI
    $ICPT Ph 3
    $IMMP Ph 2
    $VERU Ph 2
    $DMAC Ph 2
    $KLDO Ph 2
    $MREO Ph 2
    $SLS Ph 2
    $CORT Ph 2
    $CRBP Ph 2
    $PRAX Ph 2
    $AMRN Ph 2
    $ZEAL Ph 3
    $CBAY Ph 2
    $ARVN Ph 2
    $TNXP Ph 3
    $FGEN Ph 2
    Bullish
  • Y
    Yahoo Finance Insights
    CymaBay Therapeutics reached a 52 Week low at 1.87
  • C
    Chuck
    Not expecting much from these earnings. Just hoping they're not looking for more money.
    Bullish
  • C
    Chuck
    anyone back to work here yet?
    Bullish
  • b
    betasplen
    6th consecutive day of green and we hit a 52 week high in pre-market as well. I like the steady rise vs the crazy volatility. Today's ER is not about earnings - they don't have any! - but adding more color to the recent developments with regards to the Phase 3 trials for PBC and hopefully NASH as well. If they do get a partner for NASH with significant upfront payments and an equitable profit sharing agreement, this will test the high analyst target of $20 on that news alone.
  • b
    betasplen
    Sujal and co. did an admirable job of not over hyping but showing quiet confidence at the same time. They can't control the market. Remember the stock was down only 20 cents in the morning but closed another buck down by the close. Nothing to do with management. One thing I noticed - they don't give any warning for nukes. They quietly worked with the FDA and then announced the lift of all holds. They quietly unblinded the shortened PBC trial and then announced stellar results. They are probably quietly working on partnerships for NASH and PSC now and will suddenly announce that as well in 4Q20. I think the current $20 target from Cantor Fitzgerald will look ultra conservative when that happens. BTW, here are the latest upgrades in the past 2 weeks (besides the upgrades in May):
    Date Brokerage Action Rating Price Target Impact on Share Price
    8/11/2020 Raymond James Boost Price Target Strong-Buy $10.00 ➝ $11.00 High
    8/4/2020 Cantor Fitzgerald Boost Price Target Overweight $15.00 ➝ $20.00 High
    8/4/2020 HC Wainwright Boost Price Target Buy $9.00 ➝ $13.00 High
    8/4/2020 B. Riley Reiterated Rating Buy $9.00 High
    8/3/2020 Oppenheimer Initiated Coverage Buy $12.00 High
    8/3/2020 Stifel Nicolaus Boost Price Target Hold ➝ Buy $8.00 ➝ $13.00 High
    7/30/2020 Piper Sandler Initiated Coverage Overweight $12.00 High
  • b
    betasplen
    I didn't think CBAY would be affected this much by the market drop - pre-market held steady though on low volume. Added 4K more shares on this drop. This is a safe bet for me as they should only have good news to report for the rest of the year. Only slight risk is FDA not considering the recommendation of 8 liver experts to allow Phase 3 trials to start - possible but extremely low probability since there is no treatment for NASH today. As I sell off other stocks, I will just keep adding more here and hopefully at lower prices - if they so wish to sell to me.
  • b
    betasplen
    I have boosted my holdings to 22K shares as I feel very confident that this is a conservative double, if not a triple from these prices before the new year. Plenty of cash on hand and the approval from the FDA to start Phase 2b/3 trial is pretty much a given, after the expert panel recommendation last month. There may also be a partnership arrangement that will take us much higher than Roth Capital Partner's, Cantor Fitzgerald's and Evercore ISI's upgraded targets of $15 (4 bagger from here) on 5/12/20..
  • b
    betasplen
    Wish I held onto all my 20K shares from the $4s. I had a lot of conviction that this will be $15 in 2021 but became impatient when it stalled at $6 for over a month. However, I am not worried about daily fluctuations with my current position and I think that is very important if you want to make phenomenal gains in this market. It should still be worth a small fortune if we get approval for PBC and a big fortune if we get approval for NASH as well. Expecting commercial approval for PBC sometime in 2022...
  • D
    Danh
    1) Q3 eps $(0.16) beats $(0.24) estimate by 33.3%. This is a 54.29% increase over losses of $(0.35) per share from the same period last year.
    2) stopped its review of strategic options and plans to focus on reinstating the clinical development program for seladelpar in PBC
    Bullish
  • Y
    Yahoo Finance Insights
    CymaBay Therapeutics is down 7.24% to 2.05
  • j
    james
    Intercept Pharmaceuticals Will Lay Off a Quarter of Its Staff as NASH Dream Fades

    Intercept Pharmaceuticals is laying off a quarter of its staff as it ends its run as the leader in the race to treat NASH, the newly defined liver disease that was once the hope of dozens of drug companies.
    Companies in the NASH field, once among the hottest areas of development for big pharma and biotech alike, have suffered a string of disappointments in recent months. In July, Genfit (ticker: GNFT), which had been expected to bring out one of the first NASH drugs, said it was dropping its NASH program altogether.
    Now, Intercept says it is scaling back its staff due to the Food and Drug Administration’s decision in June to reject its application for approval of the company’s NASH drug. The treatment would have been the first to get the go-ahead from the regulator.
    Shares of Intercept (ICPT) fell 39.7% on June 29, when the company announced that the FDA had rejected its application for its drug obeticholic acid to be approved as a NASH treatment. The company said at the time that the FDA had told it that the expected benefit of the drug “does not sufficiently outweigh the potential risks.”
    The stock fell another 10.7% on Tuesday, when the company filed a Securities and Exchange Commission report saying it had adopted a plan to “reduce its workforce” in light of the FDA decision. The company said it would continue to develop obeticholic acid as a NASH treatment, and as a treatment for primary biliary cholangitis, another liver disease.
    Shares were up 3% on Wednesday morning.
    The stock’s collapse brings shares of the company back to earth, after an extraordinary bump that lasted nearly six years. On a single day in January 2014, the stock rose from $72.39 to $275.87 after the company announced positive results on a trial of obeticholic acid in NASH.
  • m
    me
    It looks like Avoro Capital Advisors LLC doubled their position to over 10MM shares!
  • Y
    Yahoo Finance Insights
    CymaBay Therapeutics is down 7.85% to 1.76
  • C
    Chuck
    Just the facts: After a number of upgrades, all 8 of the analysts surveyed by FactSet have the equivalent of buy ratings. Stifel Nicolaus's Derek Archila raised his rating to buy from hold and doubled his price target to $8, saying the risk-versus-reward scenario is now "highly favorable" given the panel's findings. Raymond James's Steven Seedhouse lifted his rating to outperform from market perform, saying the seladelpar development is "stunning," while SVB Leerink's Thomas Smith upgraded CymaBay to outperform from market perform and lifted his price target to $6.00 from $2.50. Separately, CymaBay reported late Monday a narrower-than-expected first-quarter loss.
    Bullish
  • j
    james
    I think what is hurting the share price is the utter lack of communication from the company. No news on any trials, no information on when earnings will be, no information of any kind. It’s been almost 3 months without anything...No wonder people are selling their shares. They should put something out just to let everyone know they are making some sort of progress. Cmon CBAY board let us know your alive!
Advertisement
Advertisement